TriangleEXL01 + Nivolumab/Ipilimumab (NCT07128680)
EXL01 + Nivolumab/Ipilimumab trial for Metastatic Clear Cell or Sarcomatoid Renal Cell Carcinoma (NCT07128680). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced or metastatic kidney cancer, clear cell or sarcomatoid.
The idea: give standard immunotherapy, nivolumab and ipilimumab, with or without EXL01. EXL01 is a live biotherapeutic product, a capsule containing a strain of gut bacteria called Faecalibacterium prausnitzii, taken by mouth. Gut bacteria may affect how well immunotherapy works.
The study looks at safety and effectiveness.
This phase 1 study plans 33 patients. At City of Hope in Duarte, California, Sumanta Pal leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.